GEN Exclusives

More »

GEN News Highlights

More »
Oct 1, 2012

Endometriosis Partnership Aims for Three Drug Candidates

  • Bayer Pharma is paying Evotec €12 million (about $15.4 million) up front as part of a five-year, multitarget partnership that aims to generate three clinical-stage drugs for treating endometriosis. Both firms will input potential targets and share early research work and the preclinical characterization of potential candidates. Bayer will then take over clinical development and commercialization activities.

    Under terms of the deal Evotec could receive up to another €580 million (roughly $746 million) in preclinical, clinical, and sales milestones, plus royalties on net sales, dependent on which firm contributed the candidate to the collaboration.

    Bayer and Evotec say estimates suggest about 10% of women of reproductive age—about 176 million women worldwide—suffer from endometriosis. “It is one of Bayer’s strategic research indications, and our new collaboration with Evotec will perfectly complement our activities in this field of high unmet medical need,” comments Andreas Busch, head of global drug discovery at Bayer HealthCare. “We look forward to working with Evotec’s team on the development of novel drug candidates.”  

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »